

2Q FY2026

# FINANCIAL RESULTS OVERVIEW





# Thank You for Your Attention

## Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations. The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should," "forecast," "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to

successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the impact relating to or arising from changes to tariffs, import/export or trade policies; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended January 31, 2026.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP measures. Non-GAAP measures exclude charges primarily related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, and net (gain) loss on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.

## Agilent 2Q26 Results

6.3% revenue growth<sup>(1)(2)</sup>  
beats high-end of  
guidance by 80 bps

Operating Margins also  
above guide by 80 bps



- Revenue of \$1.83B, led by strong high-single-digit instrument growth
- Operating margin 26.4%<sup>(2)</sup>, a 130 bps increase versus last year, as the Ignite Operating System drives pricing gains and operating efficiencies



Revenue

**\$1.83B**

+10.0% reported  
+6.3% core<sup>(1)(2)</sup>  
+3.7% FX



Operating Margin

**26.4%**<sup>(2)</sup>

+130 bps y/y  
+180 bps q/q



EPS

**\$1.49**<sup>(2)</sup>

+14% y/y



**Capital  
Allocation**

\$277M operating cash flow  
\$65M to purchase 0.55M shares  
\$76M invested in capex  
\$72M in dividends

(1) Core growth or organic constant currency is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

# Q2 results demonstrate compounding value of the Ignite Operating System

<p><b>LDG</b></p> <p><b>22.0%</b> Operating Margin<sup>(2)</sup></p>	<p><b>+9%</b></p> <p>Core Growth<sup>(1)(2)</sup> <b>+12% Reported</b></p>	<ul style="list-style-type: none"> <li>• Replacement cycle momentum with low double-digit LC &amp; LC/MS growth</li> <li>• Omnis family, CDx services drive double-digit Cancer Dx growth</li> </ul>
<p><b>AMG</b></p> <p><b>23.3%</b> Operating Margin<sup>(2)</sup></p>	<p><b>+11%</b></p> <p>Core Growth<sup>(1)(2)</sup> <b>+14% Reported</b></p>	<ul style="list-style-type: none"> <li>• Market-leading Spectroscopy tools deliver double-digit growth</li> <li>• Compelling value in tech refresh results in low double-digit GC growth</li> </ul>
<p><b>ACG</b></p> <p><b>32.0%</b> Operating Margin<sup>(2)</sup></p>	<p><b>+2%</b></p> <p>Core Growth<sup>(1)(2)</sup> <b>+6% Reported</b></p>	<ul style="list-style-type: none"> <li>• Ex-China, ACG growth was mid-single-digit, led by high-single consumables</li> <li>• Mid-single-digit Services growth</li> <li>• Tough y/y China comp on pre-tariff consumables stocking</li> </ul>

(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

Definitions: LDG: Life Sciences and Diagnostics Markets Group, ACG: Agilent CrossLab Group, AMG: Applied Markets Group, LC: Liquid Chromatography, GC: Gas Chromatography, MS: Mass Spectrometry, CDx: Companion Diagnostics




## GEOGRAPHY

## PRODUCT TYPE

Americas and Europe deliver strong broad-based growth; APAC impacted by tough China compares y/y

- Americas  
42% of Agilent Revenue<sup>(2)</sup>
- Europe  
28% of Agilent Revenue<sup>(2)</sup>
- Asia-Pacific (APAC)  
30% of Agilent Revenue<sup>(2)</sup>

### Core Revenue Growth by Geography



(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(2) % of Q2'26 Agilent revenue.



GEOGRAPHY


PRODUCT TYPE

## Q2 revenue mix

Robust growth in instruments, increasing recurring revenue mix

- Consumables  
Services  
Informatics
- Instruments

% of total revenue



# Q2 REVENUE Momentum in our largest end markets...

...supported by strong execution, replacement-cycle, and innovation-led share gains

		Q2 Core Growth <sup>(1)</sup> Results	Share of Agilent Revenue <sup>(2)</sup>
Pharma	Fifth quarter of mid-single to low-double-digit growth, including low double-digit growth in biotech	+6%	36%
Diagnostics & Clinical	Strength driven by our expanding Cancer Diagnostics offerings, including Omnis family traction	+11%	16%
Academia & Government	Muted but stabilizing research funding environment weighs on instrument spend	-5%	7%
Chemicals & Advanced Materials	Growth driven by semiconductor demand and Chemicals capex investments in the Americas	+8%	23%
Environmental & Forensics	Strong growth in Forensics supported by competitive wins and TSA airport security contract	+13%	10%
Food	Funding delays in China and India drive modest decline	-3%	8%


(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(2) % of Q2'26 Agilent revenue.

# FY26 Guidance<sup>(1)</sup>

Increasing core revenue growth<sup>(2)</sup>, margin expansion, and EPS outlook

Updated outlook reflects increased confidence in business performance and execution



(1) Based on forecasted currency exchange rates. Presented on a non-GAAP basis.


(2) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(3) The 2024 repurchase program became effective on August 1, 2024 and commenced upon completion of our 2023 repurchase program in September 2025.

# 3Q26 Guidance<sup>(1)</sup>

Expect strong H1 momentum to continue

Reflects continued healthy demand trends



\$8M  
Q3

Net Interest +  
Other Inc/(Exp)

283M  
Q3


Share  
Count

(1) Based on forecasted currency exchange rates. Presented on a non-GAAP basis.

(2) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

# Continued Growth Momentum

Updated outlook reflects accelerating 2-year stack growth across FY26



(1) Core or organic constant currency growth is reported growth adjusted for the effects of acquisitions and divestitures, and FX.

(2) Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided on Agilent's Investor Relations website.

(3) Adjusted for growth impact of weather event which reduced Q1'26 core growth by ~50bps, and increased Q2'26 core growth by ~50bps



**Agilent**  
Trusted Answers



Get in touch  
with us



[investor\\_relations@agilent.com](mailto:investor_relations@agilent.com)



[www.investor.agilent.com](http://www.investor.agilent.com)